New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023

Juan Tamargo; Stefan Agewall; Claudio Borghi; Claudio Ceconi; Elisabetta Cerbai; Gheorghe A Dan; Péter Ferdinandy; Erik Lerkevang Grove; Bianca Rocca; Emma Magavern; Patrick Sulzgruber; Anne Grete Semb; Samuel Sossalla; Alexander Niessner; Juan Carlos Kaski; Dobromir Dobrev

doi:10.1093/ehjcvp/pvae013

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023

Eur Heart J Cardiovasc Pharmacother. 2024 May 4;10(3):219-244. doi: 10.1093/ehjcvp/pvae013.

Authors

Juan Tamargo¹, Stefan Agewall^{2

3}, Claudio Borghi⁴, Claudio Ceconi⁵, Elisabetta Cerbai⁶, Gheorghe A Dan⁷, Péter Ferdinandy^{8

9}, Erik Lerkevang Grove^{10

11}, Bianca Rocca^{6

12}, Emma Magavern¹³, Patrick Sulzgruber¹⁴, Anne Grete Semb¹⁵, Samuel Sossalla^{16

17}, Alexander Niessner¹⁸, Juan Carlos Kaski¹⁹, Dobromir Dobrev^{20

21

22}

Affiliations

¹ Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, 28040 Madrid, Spain.
² Institute of Clinical Science, Oslo University, 0318 Oslo, Norway.
³ Institute of Clinical Sciences, Karolinska Institute, Danderyd Hospital, 171 77 Stockholm, Sweden.
⁴ Department of Cardiovascular Medicine, University of Bologna-IRCCS AOU S. Orsola, 40138 Bologna, Italy.
⁵ Motusmed Clinic, 25122 Brescia, Italy.
⁶ Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
⁷ Carol Davila. University of Medicine, Colentina University Hospital, 0221 Bucharest, Romania.
⁸ Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, H-1089, Hungary.
⁹ Pharmahungary Group, Budapest, H-1031, Hungary.
¹⁰ Department of Cardiology, Aarhus University Hospital, 8200 Aarhus N, Denmark.
¹¹ Department of Clinical Medicine, Faculty of Health, Aarhus University, 8200 Aarhus N, Denmark.
¹² Section of Pharmacology, Department of Safety and Bioethics, Catholic University School of Medicine, 00168 Roma, Italy.
¹³ William Harvey Research Institute, Centre of Clinical Pharmacology and Precision Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
¹⁴ Department of Medicine, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
¹⁵ Preventive Cario-Rheuma clinic, Division of Research and Innovation, REMEDY centre, Diakonhjemmet Hospital, 0370 Oslo, Norway.
¹⁶ Cardiology and Angiology, Justus-Liebig-University, D-35392 Giessen, Germany.
¹⁷ Department of Cardiology, Kerckhoff-Clinic/DZHK, D-61234 Bad Nauheim, Germany.
¹⁸ Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
¹⁹ Molecular and Clinical Sciences Research Institute, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
²⁰ Institute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen, DE-45122 Essen, Germany.
²¹ Department of Medicine, Montreal Heart Institute and Université de Montréal, H1Y 3N1 Montréal, Canada.
²² Department of Integrative Physiology, Baylor College of Medicine, 77030 Houston, TX, USA.

PMID: 38379024
PMCID: PMC11121198 (available on 2025-02-20)
DOI: 10.1093/ehjcvp/pvae013

Abstract

Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs.

Keywords: Cardiovascular drugs; Cardiovascular pharmacotherapy; Cardiovascular treatment strategies; New cardiovascular pharmacological agents.

Publication types

Review

MeSH terms

Animals
Cardiovascular Agents* / adverse effects
Cardiovascular Agents* / therapeutic use
Cardiovascular Diseases* / drug therapy
Cardiovascular Diseases* / prevention & control
Drug Development
Drug Repositioning
Humans
Treatment Outcome

Substances

Cardiovascular Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding